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Abstract - The modulatory effects of the Cyclamen trochopterantum tuber extract on hepatic drug-metabolizing enzymes, 
including  aniline  4-hydroxylase  (A4H;  CYP2E1),  ethoxyresorufin  O-deethylase  (EROD;  CYP1A),  methoxyresorufin 
O-demethylase  (MROD;  CYP1A),  caffeine N -demethylase  (C3ND;  CYP1A2)  aminopyrene  N-demethylase  (APND; 
CYP2C6), and erythromycin N-demethylase (ERND; CYP3A1), were examined in vivo in rats. The activities of all of 
these enzymes were induced by the cyclamen extract. In addition, Western-blot and RT-PCR results clearly showed that 
CYP2E1, CYP1A1/CYP1A2 and CYP2C6 protein and mRNA levels were substantially increased by four different doses of 
cyclamen. Although, the CYP3A1 protein level was increased significantly, the mRNA level was not changed. These results 
indicate that cyclamen tuber extract might have a potential not only to inhibit and/or induce the metabolism of certain 
co-administered drugs but also influence the development of toxicity and carcinogenesis due to the induction of the cyto-
chrome P450-dependent drug-metabolizing enzymes.
Key words: Cyclamen trochopteranthum, drug-metabolizing enzymes, complementary and alternative herbs, drug interac-
tion potential, cytochrome P450
UDC 582.689.1:577.15
INTRODUCTION
In recent years, the use of complementary and al-
ternative therapies mostly depending on herbs and 
herbal preparations has grown substantially. Their 
usage generally increases in areas in which conven-
tional methods have failed to provide satisfactory 
solutions to the treatment of diseases, such as in 
cancer and HIV infection. Many herbs and herbal 
preparations are natural and so they are considered 
as safe. However, the lack of critical information 
regarding the toxicity, allergenicity, mutagenicity and 
possible drug interactions of these compounds con-
stitutes a serious issue with respect to their use. It is 
well established that many herbs and herbal rem-
edies such as garlic, green tea, grapefruit, curcu-
min, echinacea, ginseng, gingko, kava kava, urtica 
and ginger interact pharmacokinetically with drugs 
by modulating both the activities and expression 
of  drug-metabolizing  enzymes,  particularly  cyto-
chrome P450s (Delgoda and Westlake, 2004; Yang 
and Raner, 2005; Ozkarsli et al., 2008; Agus et al., 
2009). Thus, in vitro and in vivo studies clarifying 
pharmacokinetic  interactions,  altered  drug  con-
centrations and enhanced bioactivation of drugs to 
reactive intermediates, which might be attributable 
to the induction and/or inhibition of cytochrome 
P450s  by  co-administered  herbs,  have  important 
clinical significance (Zhou et al., 2003).
The cytochromes P450 (CYP) are a superfami-
ly of hemoproteins that play critical roles in the 
bioactivation and detoxification of a wide variety 
of xenobiotic substances. Besides, they also have 546 SEVKI ARSLAN  ET AL.
roles in the metabolism and synthesis of endog-
enous compounds. They are mainly located in the 
smooth  endoplasmic  reticulum  membranes  as 
well as in mitochondrial inner membrane. Mul-
tiple  isozymes  of  P450  show  different  substrate 
specificities  and  affinities  toward  both  endog-
enous and exogenous compounds. Among these, 
P450s, CYP3A, CYP2C, CYP2D, CYP1A, CYP2E 
subfamilies have received a great deal of attention 
in recent years because of their ability to metabo-
lize  various  pharmaceutical  agents,  and  because 
of  their  role  in  carcinogenicity  (Sen  and  Arinc, 
1998; Chung et al., 2004). It is well established that 
CYP1A and CYP2E enzymes are mainly involved 
in carcinogen metabolism while CYP3A, CYP2D 
and CYP2C enzymes are mainly responsible for 
drug metabolisms.
The CYP3A subfamily is considered to have the 
greatest overall impact on human pharmacotherapy 
because it is the most abundantly expressed CYP 
in the human liver and small intestine. It possess-
es metabolic activity towards an extremely broad 
spectrum of xenobiotic substrates including anti-
biotic, anti-arrhythmics, sedatives, immune system 
modulators, calcium channel blockers, HIV-direct-
ed antiviral agents and HMG CoA reductase inhibi-
tors (Sugimoto et al., 2006; de Wildt et al., 2007). 
The CYP2C subfamily accounts for approximately 
20% of the total liver cytochrome P450 content in 
humans.  It  is  responsible  for  the  metabolism  of 
approximately  20%  of  all  clinically  administered 
drugs,  including  anti-coagulants,  anti-diabetic 
agents,  non-steroidal  anti-inflammatory  drugs, 
anti-convulsants (Carlile et al., 1999). Cytochrome 
P4502E, the ethanol inducible form of P450, can 
metabolize  many  low  molecular  weight  endog-
enous and exogenous compounds such as acetone, 
long chain fatty acids, benzene, chloroform, pyri-
dine,  acetaminophen,  chlorzoxazone,  trimethadi-
one and acetylsalicylic acid (aspirin) (Lieber, 1999; 
Klotz and Ammon, 1998). The CYP1A subfamily is 
responsible for the metabolism of pharmaceuticals 
and well-known human carcinogens (Adamson et 
al., 1996; Kim and Guengerich, 2005; Ma and Lu, 
2007). 
The Turkish flora includes around 12 000 plant 
species. About one third of these plants are endemic 
and most of these are used as medicines and spices 
in Turkey. Cyclamen are a genus of twenty species 
within the family Primulaceae. Cyclamen trochop-
teranthum is one of the endemic species of cycla-
mens in Turkey. It is a species that grows naturally 
in the south-western part of Turkey, especially in 
Antalya, Mugla, Denizli, Burdur, and Isparta. Many 
cyclamen species are widely used as ethno-medi-
cine for the treatment of hemorrhoids and eczema 
and expelling digestive tract worms. It was reported 
that cyclamen is also used in Turkish folk medicine 
against infertility (Calis et al., 1997). The cyclamen 
extract shows interesting spermicidal, anti-micro-
bial, anti-inflammatory and anti-nociceptive activi-
ties and is used in rhinosinusitis (Primorac et al., 
1985; Mahasneh and El-Oqlah, 1999; Speroni et al., 
2007). Despite their wide usage and diverse bio-
logical activities, there is no available information 
about the effect of cyclamens on xenobiotic me-
tabolism and possible drug interaction potential. In 
this respect; the aim of this study is to determine 
the effect of the ethanol extracts of cyclamen tubers 
on hepatic CYP450 isozymes. 
MATERIALS AND METHODS
Chemicals
The following chemicals were purchased from Sig-
ma-Aldrich Chemical Company (St Louis, Missouri, 
USA): acrylamide, aniline, anti-rabbit IgG-ALP con-
jugate, bovine serum albumin (BSA), Folin phenol 
reagent, glycerol, glycine, HEPES, β-NADPH, phe-
nol, anti-rabbit IgG-ALP conjugate, caffeine, TRIS, 
phenylmethylsulphonyl fluoride (PMSF), potassium 
dihydrogen phosphate, dipotassium hydrogen phos-
phate, sodium dodecyl sulfate (SDS), sodium potas-
sium tartrate. Anti-rat CYP1A2, CYP2C6, CYP2E1 
and CYP3A1 antibodies were from Abcam (Abcam 
PLC, Cambridge, UK). Iblot Transfer Stack was pur-
chased from Invitrogen Corporation, (Carlsbad, CA, 
USA).  All  other  chemicals  and  solvents  were  ob-
tained from commercial sources at the highest grade 
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Preparation of the Cyclamen  
trochopteranthum tuber extract
The fresh tubers of Cyclamen trochopteranthum used 
in the present study were collected from Denizli, Tur-
key. The tubers (200 g) were first peeled, cut into 5 
mm × 5 mm cubes. These tubers were extracted two 
times with ethanol at 55°C. The ethanol extract was 
then dried under a vacuum in a rotary evaporator 
and the remaining material was ground into a fine 
powder. The powder was then lyophilized and stored at 
-80°C until usage.
Standardization of Cyclamen trochopteranthum  
tuber extract
The total concentration of phenolic compounds in the 
extracts was determined using a series of gallic acid 
standard solutions (0.05-0.3 mg/mL) as described by 
Singleton and Rossi (1965). Results were expressed 
as milligrams of total phenolics content per grams of 
extract as gallic acid equivalents (GAE).
Animals and treatment
Healthy male Wistar rats, about 12 weeks old and 
weighing 200–250 g, were obtained from the Uni-
versity Animal House. They were housed in small 
cages at an ambient temperature of 22 ± 1°C, on a 12 
h light/dark cycle and were fed commercial rat food 
with water ad libitum. All experimental procedures 
with the animals were performed under appropriate 
regimes with veterinary services within the licensed 
projects. Since no data are available on the consump-
tion habit of cyclamen we had carried out prelimi-
nary pilot studies involving the dose-response activi-
ties to find out the right doses without any toxic side 
effects (data not shown). In addition, the extract was 
given to the animals in drinking water in order to 
correspond to human use. After a 10 day adaptation 
period, the rats were divided into five groups consist-
ing of 4-8 animals each. The first group consisted of 
control animals administered water without extract. 
The other groups were treated with cyclamen extract 
at doses of 0.1, 0.2, 0.5 and 1.0 mg/ml in drinking 
water for 10 consecutive days. At the end of the ex-
perimental period and following 16 h of fasting, the 
rats were killed; the livers were removed, rinsed with 
cold physiological saline and stored at -80°C until 
analyses. 
microsome preparation
Tissues were homogenized in 4 part homogenization 
solution [1.15% KCl containing 3 mM EDTA, 0.5 
mM PMSF, 0.3 mM ε-aminocaproic acid, 0.15 mM 
butylated hydroxytoluene, 0.025% Triton X-100] us-
ing a tissue homogenizer with a Teflon pestle at 4°C. 
Subcellular fractions of rat tissues were prepared by 
standard differential centrifugation with calcium ag-
gregation as described by Sen and Kirikbakan (2004). 
The amount of protein in individual fractions was 
measured using the method of Lowry et al. (1951) 
with BSA as the standard.
enzyme assays
Serum  aspartate  aminotransferase  (AST),  alanine 
aminotransferase (ALT) and lactate dehydrogenase 
(LDH) activities were determined with an autoana-
lyzer using Audit diagnostics AST, ALT and LDH 
enzyme  kits.  The  microsomal  cytochrome  P450-
dependent  aniline  4-hydroxylase  (A4H)  activities 
of rat microsomes were determined by measuring 
the quantity of p-aminophenol formed, as described 
by Imai et al. (1966). Aminopyrene N-demethylase 
(APND), erythromycin N-demethylase (ERND) and 
caffeine N-demethylase (C3ND) activities were de-
termined by measuring the quantity of formaldehyde 
formed, according to the method of Nash (1953) and 
modified by Cochin and Axelrod (1959). Ethoxyre-
sorufin  O-deethylase  (EROD),  methoxyresorufin 
O-demethylase (MROD) activities were assayed as 
described by Sen and Arinc (1998).
Gel electrophoresis and Western blotting
SDS-PAGE and Western blotting were performed as 
described previously (Sen and Arinc, 1998). Briefly, 
120 μg protein samples were separated on 8.5% poly-
acrylamide gels using the discontinuous buffer sys-
tem of Laemmli (1970). Proteins were transferred to 548 SEVKI ARSLAN  ET AL.
a nitrocellulose membrane by the iBlot dry blotting 
system (20 V, 12 min), using iBlot gel transfer stacks. 
Following  transfer,  the  membranes  were  blocked 
using 5% non-fat dry milk in TBST (20 mM Tris-
HCl, pH 7.4, 400 mM NaCl and 0.1% (v/v) Tween 
20) for 60 min and incubated with rabbit polyclonal 
anti-rat CYP1A2, CYP2C6, CYP2E1 or CYP3A1 an-
tibodies (diluted 1:1000 in blocking solution) for 120 
min at room temperature. The membranes were then 
washed with TBST (3 × 5 min), incubated with the 
secondary antibody (ALP-conjugated anti-rabbit IgG 
at a 1:5000 or 1:10000 dilution) for 60 min and again 
washed with TBST (3 × 5 min). Visualization of the 
bands was carried out using the NBT/BCIP substrate 
system. The final images were photographed by us-
ing computer-based gel imaging instrument (DNR 
LightBIS Pro Image Analysis System, Israel). Protein 
bands  were  quantified  using  Scion  Image  Version 
Beta 4.0.2 software.
RNA isolation and RT-PCR of CyP mRNAs
Total RNA was extracted from 100 mg rat livers 
using Trizol reagent. Extracted RNA was quanti-
fied spectrophotometrically at 260/280 nm and the 
integrity  was  checked  using  1%  agarose  gel.  For 
cDNA synthesis, 2.5 µg of RNA was incubated at 
70°C for 10 minutes with 0.5 µg of oligo(dT). After 
5 min on ice, 50 U Moloney murine leukemia virus 
reverse transcriptase, 1 mM dNTPs and 5X reaction 
buffer were added to the previous mixture and incu-
bated at 42ºC for 60 min. The reaction was stopped 
by heating to 70°C for 10 min and the cDNA was 
stored at -80°C for further use.
Semi-quantitative two-step RT-PCR assay was 
performed  by  using  gene  specific  primers.  The 
oligo sequences used as forward and reverse prim-
ers for rat CYP450 isozymes were based on those 
reported in Agus et al. (2009). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and β-actin 
were  used  as  a  housekeeping  gene.  Preliminary 
control experiments (data not shown) were car-
ried out to verify the RT-PCR conditions allowed 
for linear amplification of PCR products. The PCR 
products were analyzed by electrophoresis on 1.5% 
agarose gels containing ethidium bromide. The in-
tensity of the bands was measured using Scion Im-
age Version Beta 4.0.2 software. Levels of mRNA 
for CYP genes were determined by measuring the 
band  intensity  of  the  RT-PCR  product  on  each 
agarose gel and are reported relative to GAPDH or 
β-actin expression.
Statistical analysis
Statistical  analyses  were  performed  by  using  the 
Minitab statistical software package. All results were 
expressed  as  means  with  their  Standard  Error  of 
Means (SEM). Comparison between two groups was 
Table 1.  Blood serum LDH, AST and ALT enzyme activities in control and cyclamen treated rats.
Lactate Dehydrogenase 
(LDH) 
Unit/min/mg protein
Change
(Fold)
Aspartate  
Aminotransferase 
(AST) 
Unit/min/mg protein
Change
(Fold)
Alanine Aminotransferase 
(ALT) 
Unit/min/mg protein
Change
(Fold)
Control 11.08 ± 0.96 -- 1.51 ± 0.14 --
1.36 ± 0.09
--
0.1 mg/ml Cyclamen  12.62 ± 2.9 1.1 X ↑ 1.55 ± 0.38 1.02 X ↑ 1.38 ± 0.08 1.01 X ↑
0.2  mg/ml Cyclamen 11.74 ± 0.34 1.06 X ↑ 1.57 ± 0.07    1.04 X ↑ 1.51 ± 0.04 1.11 X ↑
0.5  mg/ml Cyclamen 13.68 ±  0.74 1.23 X ↑ 1.68 ± 0.12 1.11 X ↑ 1.54 ± 0.07 1.13 X ↑
1.0  mg/ml Cyclamen 22.6 ± 7.0*   2.04 X ↑ 2.74 ± 0.70*     1.81 X ↑ 1.72±  0.04* 1.26 X ↑
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performed by Student’s t-test and p<0.05 was cho-
sen as the level for significance. Statistical compari-
sons between five groups were assessed by one-way 
analysis of variance (ANOVA). When F ratios were 
significant (p<0.05), one-way ANOVA was followed 
by Tukey’s post hoc test for comparisons of multiple 
group means.
RESULTS
Cyclamen tuber extract was applied to rats in drink-
ing water at four different doses. Control and treat-
ed  rats  showed  no  significant  differences  in  food 
consumption or body weight (data not shown). As 
shown in Table 1, blood serum AST, ALT and LDH 
Table 2.  Stimulation of Erythromycin  N-demethylase and Aminopyrene N-demethylase activities in liver of cyclamen treated rats..
Erythromycin 
N-demethylase
(nmol HCHO/min/mg prot.)
Change
(Fold)
Aminopyrene 
N-demethylase 
(nmol HCHO/min/mg prot.)
Change
(Fold)
Control 0.03± 0.0033 (N=8) --
0.023 ± 0.003 (N=8)
--
0.1 mg/ml Cyclamen  0.066 ± 0.011* (N=4) 2.20 X ↑ 0.026 ± 0.005 (N=4) 1.13 X ↑
0.2  mg/ml Cyclamen 0.0780 ± 0.004*** (N=4) 2.60 X ↑ 0.025 ± 0.002 (N=4) 1.09 X ↑
0.5  mg/ml Cyclamen 0.0420 ± 0.006 (N=4) 1.40 X ↑ 0.031 ± 0.004 (N=4) 1.35 X ↑
1.0  mg/ml Cyclamen 0,050 ± 0.007* (N=4) 1.67 X ↑ 0.046 ± 0.002** (N=4) 2.00 X ↑
  *Significantly different from the respective control value p<0.05
  **Significantly different from the respective control value p<0.005
  ***Significantly different from the respective control value p<0.0001
Table 3.  Changes of Aniline 4-hydroxylase, Ethoxyresorufin O-deethylase, Methoxyresorufin O-demethylase and  Caffeine N-demeth-
ylase  activities in liver of cyclamen treated rats.
Aniline 4-hydroxylase 
(nmol HCHO/min 
/mg prot.)
Change
(Fold)
Ethoxyresorufin 
O-deethylase
 (pmol Resorufin/ 
min/mg prot.)
Change
(Fold)
Methoxyresorufin  
O-demethylase
(pmol Resorufin/ 
min/mg prot.)
Change
(Fold)
Caffeine N-demethylase 
(nmol HCHO/min/mg 
prot.)
Change
(Fold)
Control 0.15± 0.008 (N=8) --
0.60 ± 0.07 (N=8)
--
3.57 ± 0.6 (N=8)
--
0.049 ± 0.007 (N=8)
--
0.1 mg/ml  
Cyclamen 
0.33 ± 0.011* (N=4) 2.20 X ↑ 1.76 ± 0.36* (N=4) 2.93 X ↑ 7.91 ± 1.5* (N=4) 2.21 X ↑ 0.077 ± 0.008* (N=4) 1.57X ↑
0.2  mg/ml  
Cyclamen
0.20 ± 0.004 **(N=4) 1.33 X ↑ 1.23± 0.033* (N=4) 2.05 X ↑ 8.19± 1.8*(N=4) 2.29 X ↑ 0.056 ± 0.003 (N=4) 1.14 X ↑
0.5  mg/ml  
Cyclamen
0.18 ± 0.008* (N=4) 1.20 X↑ 0.91 ± 0.09* (N=4) 1.52X ↑ 7.85 ± 1.2* (N=4) 2.20X ↑ 0.098 ± 0.008* (N=4) 2.00 X ↑
1.0  mg/ml  
Cyclamen
0.29 ± 0.01*** (N=4) 1.93 X ↑ 0.35 ± 0.07* (N=4) 1.86 X ↑10.39 ± 0.4*** (N=4)2.91 X ↑ 0.075 ±  0.006* (N=4) 1.53 X ↑
*Significantly different from the respective control value p<0.05
**Significantly different from the respective control value p<0.005
***Significantly different from the respective control value p<0.0001550 SEVKI ARSLAN  ET AL.
activities  were  increased  compared  to  the  control 
rats. With the highest dose of cyclamen treatment 
the increases of AST, ALT and LDH activities were 
found to be significant (p<0.05) whereas other doses 
were not (Table 1).
The total phenolic content of the C. trochopter-
anthum tuber extract was determined by the method 
of Singleton and Rossi (1965) and the results are ex-
pressed as mg per g of gallic acid equivalents (GAE) 
to standardize the extract. The amount of total phe-
nolic compounds found in the extract of Cyclamen 
trochopteranthum tuber extract was 16.4 ± 0.5 mg 
GAE per g extract.
As presented in Table 2, hepatic CYP3A1-as-
sociated ERND activity was increased 2.20-, 2.60-, 
1.40- and 1.67-fold in cyclamen-treated rats when 
compared to control ones. These increases were 
found to be significant (p<0.05) in cyclamen-treat-
ed rats at a dose of 0.1, 0.2, and 1.0 mg/ml whereas 
at that of 0.5 mg/ml they were not (Table 2). On 
the other hand, 0.1, 0.2 and 0.5 mg/ml cyclamen 
extract  treatment  did  not  change  the  CYP2C6-
Fig. 1. The expression levels of CYP2E1 and CYP1A2 proteins and mRNAs in control rats and rats treated with C. trochopter-
anthum. Treatments were carried out as described in Materials and Methods. a. Representative immunoblot analysis of liver 
microsomal CYP2E1 proteins in experimental groups. Lane 1, control; Lanes 2 to 5 different doses of cyclamen treatment. b. 
Representative agarose gel showing the effect of treatments on regulation of CYP2E1 mRNA expressions in liver, analyzed by RT-
PCR. Lane 1, 1 KB DNA ladder; Lane 2, CYP2E1 in control; Lanes 3, 4, 5 and 6, CYP2E1 in cyclamen-treated rats. c. Comparison 
of CYPE1 protein and mRNA levels among experimental groups. The bar graphs represent the mean intensity of the bands ob-
tained from Western blot and/or RT-PCR results. d. Representative immunoblot analysis of liver microsomal CYP1A2 proteins in 
experimental groups. Lane 1, control; Lanes 2 to 5 different doses of cyclamen treatment. e. Representative agarose gel showing 
the effect of treatments on regulation of CYP1A2 mRNA expressions in liver, analyzed by RT-PCR. Lane 1, 1 KB DNA ladder; 
Lane 2, CYP1A2 in control; Lanes 3, 4, 5 and 6, CYP1A2 in cyclamen-treated rats. f. Comparison of CYP1A2 protein and mRNA 
levels among experimental groups. 
Experiments were repeated at least three times. Results are presented as mean ± standard deviation. * p < 0.05.EFFECTS OF CyClAmeN ON P450S 551
associated APND activity significantly in rat liver 
(Table 2). In contrast, in the 1 mg/ml group this 
activity was increased around 2-fold with respect 
to control rats.
The  effect  of  the  cyclamen  tuber  extract  on 
CYP2E1-associated A4H activity is presented in Ta-
ble 3. Cyclamen extract treatment at a dose of 0.1, 
0.2, 0.5 and 1.0 mg/ml in drinking water for 10 con-
secutive days caused a statistically significant 2.20-, 
1.33-, 1.20- and 1.93-fold increase in A4H activity in 
the liver, respectively. CYP1A-associated EROD and 
MROD  activities  in  control  and  cyclamen-treated 
rats are given in Table 3. As can be seen, EROD ac-
tivity was increased 2.93-fold (p<0.05) in the low-
est dose (0.1 mg/ml) of cyclamen extract. When the 
dose of cyclamen was increased, the extent of EROD 
induction decreased and was finally inhibited 1.86-
fold (p<0.05) at the highest dose of cyclamen ex-
tract (1.0 mg/ml). On the other hand, treatment of 
rats with four different concentrations of cyclamen 
extract caused 2.21-, 2.29-, 2.20- and 2.91-fold in-
Fig. 2. The expression level of CYP2C6 and CYP3A1 protein and mRNAs in control rats and rats treated with C. trochopteranthum. 
Treatments were carried out as described in Materials and Methods. a. Representative immunoblot analysis of liver microsomal CYP2C6 
proteins in experimental groups. Lane 1, CYP2C6 protein in control; Lanes 2 to 5 CYP2C6 protein in different doses of cyclamen treat-
ment. b. Representative agarose gel showing the effect of treatments on regulation of CYP2E1 mRNA expressions in liver, analyzed by 
RT-PCR. Lane 1, 1 KB DNA ladder; Lane 2, CYP2C6 in control; Lanes 3, 4, 5 and 6, CYP2C6 in cyclamen-treated rats. c. Comparison 
of CYP2C6 protein and mRNA levels among experimental groups. The bar graphs represent the mean intensity of the bands obtained 
from Western blot and/or RT-PCR results. d. Representative immunoblot analysis of liver microsomal CYP3A1 proteins in experimen-
tal groups. Lane 1, CYP3A1 proteins in control; Lanes 2 to 5, CYP3A1 proteins in different doses of cyclamen treatment. e. Representa-
tive agarose gel showing the effect of treatments on regulation of CYP3A1 mRNA expressions in liver, analyzed by RT-PCR. Lane 1, 1 
KB DNA ladder; Lane 2, CYP3A1 in control; Lanes 3, 4, 5 and 6, CYP3A1 in cyclamen-treated rats. f. Comparison of CYP3A1 protein 
mRNA levels among experimental groups. The bar graphs represent the mean intensity of the bands obtained from Western blot and/
or RT-PCR results
Experiments were repeated at least three times. Results are presented as mean ± standard deviation. * p < 0.05.552 SEVKI ARSLAN  ET AL.
creases in MROD activity with respect to the control 
(Table 3). The effect of different concentrations of cy-
clamen extract on CYP1A2-dependent C3ND activ-
ity was also determined throughout in this study. 0.1, 
0.2, 0.5 and 1.0 mg/ml cyclamen extract in drinking 
water caused a statistically significant 1.57-, 1.14-, 
2.0- and 1.53-fold increase in the C3ND activity in 
liver, respectively.
Activation  of  catalytic  activities  was  gener-
ally  consistent  with  the  protein  levels  of  related 
CYP isoforms in rat liver microsomes that were 
prepared from control and cyclamen-treated rats 
(Figs.  1  and  2).  The  densitometric  scanning  of 
Western blot results showed that hepatic CYP2E1 
protein  level  was  increased  significantly  1.5-fold 
in the cyclamen-treated rats relative to the con-
trol animals. Similarly, CYP1A2 protein level was 
increased (1.75-8.20-fold) by increasing doses of 
cyclamen  extract  (Fig.  1).  Moreover,  cyclamen 
treatment caused induction of the CYP2C6 protein 
level (Fig. 2). Also, 1.65 to 4.76-fold induction of 
the CYP3A1 protein level was observed as a result 
of different doses of cyclamen treatment with re-
spect to control rats (Fig. 2). 
The effect of cyclamen extract on the mRNA lev-
els of CYP isozymes was also determined through-
out in this study. The relative CYP2E1 mRNA level 
was increased up to 8.8-fold in the cyclamen-treated 
rats compared to the control animals (Fig. 1). Simi-
larly,  CYP1A2  levels  were  increased  significantly 
2.35-,  10.65-,  3.00-  and  5.65-fold  in  cyclamen-
treated rats at a dose of 0.1, 0.2, and 1.0 mg/ml 0.1 
mg/ml, respectively (Fig. 1). Similar to CYP2E1 and 
CYP1A2,  CYP2C6  mRNA  levels  were  increased 
significantly, from 1.60- to10.98-fold, as a result of 
the cyclamen treatment (Fig. 2). On the other hand, 
the cyclamen treatment did not change the relative 
CYP3A1 mRNA level with respect to the control 
rats (Fig. 2).
DISCUSSION
Interest in herbal remedies is on the increase in the 
Western  world.  However,  organ  toxicities  of  the 
heart, liver, blood, kidneys, central nervous system, 
skin and carcinogenesis due to adverse drug reac-
tions and poisonings associated with the use of herb-
al medicines have also increasingly been reported. 
(Deng, 2002; Klepser and Klepser, 1999). The most 
important factor that is mainly involved in the de-
velopment of these undesired effects is both the in-
duction and inhibition of CYP450-dependent drug-
metabolizing enzymes of many herbs (Zhou et al., 
2003). In this study, for the first time, the inductive 
effect of cyclamen on P450 isozymes was shown by 
an increase of associated enzyme activities in paral-
lel to significant protein and mRNA induction in rat 
liver.
The amount of total phenolics was found to be 
16.4 ± 0.5 mg GAE per g dry extract. Phenolic acids 
have repeatedly been implicated as natural antioxi-
dants in fruits, vegetables, and other plants. The high 
phenolic content suggests that the cyclamen extract 
has a reasonably high antioxidant activity.
It is well established that, LDH, AST and ALT 
alone or in combination are primarily recommended 
for  the  assessment  of  hepatocellular  injury  in  ro-
dents  and  non-rodents  in  non-clinical  studies.  In 
this study, the activities of LDH, AST and ALT in the 
blood serum were increased in cyclamen-treated rats 
with respect to controls. The observed increases in 
serum might be an indication of mild tissue damage 
due to cyclamen treatment.
Cyclamen extract treatment caused an increase 
in CYP3A-associated ERND activity in rat liver mi-
crosomes. Similar to the observation in this study, 
the induction of liver CYP3A-associated enzyme ac-
tivity by various plant extracts such as St John’s wort 
extract and Ginkgo biloba extract, was shown (Dürr 
et al., 2000). The results of this study show that drug 
interactions and clinical toxicity are likely to occur 
if the cyclamen extract is taken simultaneously with 
a broad spectrum of drugs. The effects of cyclamen 
extract on CYP3A1 protein and mRNA levels were 
investigated  in  order  to  determine  the  underlying 
mechanism  of  the  increase  in  CYP3A1-associated 
enzyme activity. Although the CYP3A1 protein lev-EFFECTS OF CyClAmeN ON P450S 553
el was increased significantly, the mRNA level was 
not  changed.  Different  posttranslational  increases 
in CYP3A have been reported (Zangar et al., 1997). 
Analogous to their results, our studies suggest point 
to an increase in CYP3A1 activity and protein con-
tent by protein stabilization.
Treatment with the cyclamen extract caused a 
significant  increase  in  CYP2C6-associated  APND 
activity only at the highest dose. On the other hand, 
both the CYP2C6 protein and mRNA level were in-
duced by cyclamen in four different doses. Similarly, 
Kuo et al. (2006) has shown that a CYP2C-inducing 
agent is present in the ethyl acetate extract of Salvia 
miltiorrhiza. Thus, C. trochopteranthum might pos-
sess  CYP2C-inducing  agents.  The  results  of  the 
present study showed that alterations of drug clear-
ance and clinical drug toxicity could be observed due 
to induction CYP2C in people who used cyclamen as 
a herbal remedy. 
Intake of the cyclamen tuber extract at doses of 
0.1, 0.2, 0.5 and 1.0 mg/ml in drinking water for 10 
consecutive days increased A4H activity in the liv-
er. Densitometric analysis of Western blots showed 
that the hepatic CYP2E1 protein level was increased 
significantly in the cyclamen-treated rats relative to 
the control animals. Some other herbs or chemical 
compounds isolated from herbs caused the induc-
tion of not only CYP2E1 catalytic activity but also 
its  protein  level  (Bray  et  al.,  2002).  Cytochrome 
P4502E1 has received a great deal of attention in 
recent years because of its vital role in the activa-
tion of many low molecular weight toxic chemicals 
such as benzene, CCl4, nitrosamines and pyridine 
(Guengerich et al., 1991; Arinc et al., 2000). The 
results of the present work indicate that cyclamen 
could stimulate the metabolic activation of N-ni-
trosodimethylamine, pyridine, benzene (and other 
toxic chemicals metabolized by CYP2E1) by induc-
ing CYP2E1 which results in increased amounts of 
reactive metabolites formation. This may in turn 
further potentiate the risk of organ toxicity, muta-
genesis and malignant transformation in the liver 
of these subjects. Administration of the cyclamen 
extract increased the CYP2E1 mRNA level too. The 
regulation of CYP2E1 expression is complex, involv-
ing transcriptional, post-transcriptional, and post-
translational events with polymorphism playing a 
role (Song, 1995). Therefore, the observed mRNA 
increase resulting from cyclamen treatment could 
be  either  transcriptional  or  post-transcriptional; 
this remains to be elucidated.
Among all cytochrome P450 isoforms, CYP1A 
holds priority due to its role in the metabolism of car-
cinogens, mutagens and environmental pollutants. In 
this study, CYP1A1/CYP1A2-associated enzyme ac-
tivities, EROD, MROD and C3ND, were increased as 
a result of cyclamen treatment. CYP1A2 protein and 
mRNA levels were also increased during treatment 
with four different doses of cyclamen extract. Similar 
to cyclamen, many herbs and their extracts, such as 
Salvia miltiorrhizа, caused the induction of CYP1A-
related enzyme activities and protein levels (Kuo et 
al., 2006). This work indicates that the induction of 
CYP1A by cyclamen stimulates the metabolic acti-
vation of benzo(a)pyrene, aromatic and heterocyclic 
amines. As a result of this metabolic activation, or-
gan toxicity, mutagenesis and carcinogenesis may be 
observed. It is well established that the Aryl hydro-
carbon Receptor (AhR) acts as a transcription factor 
to regulate multiple genes including the CYP1A fam-
ily. Therefore, the induction of CYP1A by cyclamen 
administration may be caused by the upregulation of 
the AhR.
In  conclusion,  based  on  the  observed  altera-
tions in CYP450 activities, cyclamen would be ex-
pected to change the disposition of other essential 
medications,  including  antibiotics,  anti-arrhyth-
mics, immune modulators, antihistamines, calcium 
channel blockers, HMG CoA reductase inhibitors, 
steroids,  proton  pump  inhibitors,  antiepileptics, 
and NSAIDs. On the basis of its nondiscriminatory 
effects on a number of important drug-metaboliz-
ing enzymes, the cyclamen extract could in princi-
ple affect the actions of many medicines. Therefore, 
until further clinical drug interaction experiments 
are completed, the co-administration of drugs with 
the cyclamen preparation should be avoided. More-
over, the results of the present study indicate that 554 SEVKI ARSLAN  ET AL.
the cyclamen extract stimulates the metabolic ac-
tivation of the toxic chemicals metabolized by not 
only CYP2E1 but also CYP1A1/1A2 by inducing 
these enzymes which results in increased amounts 
of reactive metabolite formation. This may in turn 
further potentiate the risk of toxicity and carcino-
genesis in these subjects. Therefore some precau-
tions should be taken in terms of reduction of cy-
clamen usage.
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